— Know what they know.
Not Investment Advice

MBOT NASDAQ

Microbot Medical Inc.
1W: -1.2% 1M: -25.9% 3M: -44.0% YTD: -55.4% 1Y: -61.9% 3Y: -30.2% 5Y: -86.8%
$1.03
+0.09 (+9.38%)
After Hours: $1.06 (+0.03, +2.91%)
Weekly Expected Move ±6.2%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Medical - Devices · Tech Score Sell · Power 29 · $69.2M mcap · 61M float · 1.11% daily turnover · Short 37% of daily vol
Credit Risk of going bust: lower than 65% of companies Debt: 1.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.8%), Microbot Medical Inc. would be worth roughly what it owes.
Total debt $876K against a stock market value of $63.2M.
Distance to default 6.78 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $601K (short-term plus half of long-term), stock volatility 66.8%; Altman Z 6.77. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$69.2M
52W Range0.93-2.86
Volume1,112,928
Avg Volume677,897
Beta1.05
Dividend—
Analyst Ratings
3 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOHarel Gadot
Employees43
SectorHealthcare
IndustryMedical - Devices
IPO Date1992-03-25
175 Derby Street
Hingham, MA 02043
US
781 875 3605
About Microbot Medical Inc.

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Stockburger Aileen P A-Award 10,000 $2.37 2026-04-01
Madden Martin J. A-Award 10,000 $2.37 2026-04-01
Wenderow Tal Baruch A-Award 10,000 $2.37 2026-04-01
Wilson David James A-Award 10,000 $2.37 2026-04-01
Burell Scott R A-Award 10,000 $2.37 2026-04-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms